Niche PTM CRO AVMBioMed specializes in post-translational modification discovery using Snapshot Proteomics, presenting a targeted CRO opportunity for researchers seeking novel PTM insights, enzyme-substrate relationships, and biomarker discovery.

Early-stage Focus With a current team of 0-1 employees and revenue in the sub-million range, AVMBioMed represents an opportunity to partner on feasibility studies, pilot projects, and funded collaborations to de-risk early-stage protein science initiatives.

Biomarker Discovery Their PTM-centric platform can generate novel biomarkers from cell extracts and patient samples, enabling partnerships with biotech and pharma companies pursuing diagnostics, companion diagnostics, or targeted therapies.

Academic & Preclinical Position AVMBioMed as a supplier for basic science validation, target validation, and preclinical compound characterization, appealing to mid-to-late-stage CRO buyers seeking specialized PTM data.

Strategic Partnerships Leverage proximity to big biotech ecosystems near Philadelphia and strong cloud and web tech stack to propose scalable, joint-development contracts, service packages, and data-driven collaboration models.